Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20065142 | 0.84 | KDM1A (0.49) | KDM1AKCNH2KDM1BKDM4EALDH1A1 | |
| SCHEMBL20073946 | 0.84 | KDM1A (0.49) | KDM1AKCNH2KDM1BKDM4EALDH1A1 | |
| SCHEMBL25831193 | 0.84 | KDM1A (0.49) | KDM1AKCNH2KDM1BKDM4EALDH1A1 | |
| SCHEMBL8405636 | 0.84 | KDM1A (0.49) | KDM1AKCNH2KDM1BKDM4EALDH1A1 | |
| SCHEMBL25831240 | 0.84 | KDM1A (0.49) | KDM1AKCNH2KDM1BKDM4EALDH1A1 | |
| SCHEMBL20065133 | 0.84 | KDM1A (0.49) | KDM1AKCNH2KDM1BKDM4EALDH1A1 | |
| SCHEMBL20074021 | 0.84 | KDM1A (0.49) | KDM1AKCNH2KDM1BKDM4EALDH1A1 | |
| SCHEMBL29970944 | 0.84 | KDM1A (0.49) | KDM1AKCNH2KDM1BKDM4EALDH1A1 | |
| SCHEMBL29970601 | 0.84 | KDM1A (0.49) | KDM1AKCNH2KDM1BKDM4EALDH1A1 | |
| SCHEMBL2198121 | 0.83 | TSHR (0.44) | ALDH1A1TSHRSLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977372-B2 | Ortho aminoamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977372-B2 | Ortho aminoamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977372-B2 | Ortho aminoamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| WO-2010094678-A1 | NOVEL ORTHO-AMINOAMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100216806-A1 | ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216806-A1 | ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216806-A1 | ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216806-A1 | ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER | HDAC5, HDAC1, HDAC4 | KDM1A 57/4885KCNH2 4108/4885KDM1B 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.